⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3855104 | 0.97 | — | — | |
| SCHEMBL23299194 | 0.89 | EPHX1 (0.30) | — | |
| SCHEMBL2223826 | 0.88 | CA1 (0.35) | — | |
| SCHEMBL636442 | 0.88 | — | — | |
| SCHEMBL22349450 | 0.87 | CA12 (0.35) | — | |
| SCHEMBL12311384 | 0.87 | PIK3CD (0.31) | — | |
| SCHEMBL21943789 | 0.86 | CA1 (0.39) | — | |
| SCHEMBL12033882 | 0.86 | CA1 (0.39) | — | |
| SCHEMBL720094 | 0.82 | GABRA1 (0.50) | — | |
| SCHEMBL20625192 | 0.82 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118355012-A | Novel heterocyclic substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect and pharmaceutical composition containing the same | 昂科比克斯有限公司 | 2024-07-16 | — | — | CN | claimed |
| WO-2024072075-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 테라펙스 | 2024-04-04 | — | — | WO | claimed |
| CN-112739701-B | Fused pyrimidine skeleton sulfonamide derivative with inhibition effect of epidermal growth factor receptor mutation | 韩美药品株式会社 | 2024-02-13 | — | — | CN | claimed |
| EP-3722292-B1 | NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ONCOBIX CO LTD (KR) | 2023-11-01 | — | — | EP | claimed |
| CN-111386266-B | Pyrimidine derivatives having cancer cell growth inhibiting effect and pharmaceutical compositions containing the same | 昂科比克斯有限公司 | 2023-08-04 | — | — | CN | claimed |
| CN-115190762-A | Novel substituted sulfonylurea and sulfonimidurea derivatives | 兹杜斯生命科学有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-109251588-B | Inorganic nano material ink, preparation method and application thereof, and QLED device | TCL科技集团股份有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3458455-B1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | claimed |
| US-10604527-B2 | Pyrazine compounds for the treatment of hepatitis B infection | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | claimed |
| WO-2020060268-A1 | NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT | 한미약품 주식회사 | 2020-03-26 | — | — | WO | claimed |
| EP-3131906-A1 | SUBSTITUTED PYRIDINE COMPOUNDS HAVING HERBICIDAL ACTIVITY | BASF SE (DE) | 2017-02-22 | — | — | EP | claimed |
| WO-2015158565-A1 | SUBSTITUTED PYRIDINE COMPOUNDS HAVING HERBICIDAL ACTIVITY | BASF SE (DE) | 2015-10-22 | — | — | WO | claimed |
| US-20150266878-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-09-24 | — | — | US | claimed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | claimed |
| EP-2024359-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DECEASE AND/OR SCHIZOPHRENIA | AstraZeneca AB (SE) | 2009-02-18 | — | — | EP | claimed |
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | claimed |
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | claimed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| EP-1846394-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | claimed |
| WO-2006082392-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | claimed |